Eli Lilly is buying Verve Therapeutics, developer of gene-editing treatments for cardiovascular disease, for $1 billion plus ...

The Medicare pay bump for doctors that was part of the House version of Republicans’ tax bill was dropped in the Senate’s ...

Historically, ACIP has been one of the most transparent federal committees, they wrote, with rigorous reporting on conflicts ...

As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech ...

China is a one of the most important regions for the booming obesity market, thanks to government incentives and changing ...

AI developer Nabla has raised $70 million as the company looks to expand the capabilities of its software that automates ...

Many focus on what weight-loss drugs take away: pounds. But they also offer patients something new: a sense of agency.

Eli Lilly said Tuesday that it will acquire Verve Therapeutics, a biotech developing gene-editing therapies for cardiovascular disease.

Humana leaders asserted at the company’s investor day Monday that there’s still money to be made on Medicare Advantage ...

A federal judge ruled that some of the grant terminations by the National Institutes of Health on DEI grounds are “void and ...

A private equity firm will finance a Harvard University research lab, a possible template for the future as schools ...

In today's Pharmalittle roundup, we're reading about a Lilly deal, a gene therapy shock for Duchenne families, and more.